International Journal of Pharmaceutical Compounding

A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

LEARN MORE

Nimodipine Compounded Oral Suspension: A True Documented Medical Need

Author(s): McElhiney Linda F

Issue: Mar/Apr 2019 - Volume 23, Number 2
View All Articles in Issue

Page(s): 106-111

Nimodipine Compounded Oral Suspension: A True Documented Medical Need Page 1

Nimodipine Compounded Oral Suspension: A True Documented Medical Need Page 2

Nimodipine Compounded Oral Suspension: A True Documented Medical Need Page 3

Nimodipine Compounded Oral Suspension: A True Documented Medical Need Page 4

Nimodipine Compounded Oral Suspension: A True Documented Medical Need Page 5

Nimodipine Compounded Oral Suspension: A True Documented Medical Need Page 6

Download in electronic PDF format for $75

Abstract: What happens when there is an entire patient population, not just a specific patient, which cannot take a commercial product due to significant adverse effects, although the commercial product has a U.S. Food and Drug Administration-approved indication for the medical problem? What should or can be done in this situation? This article discusses this dilemma using a subarachnoid hemorrhage as an example of a true documented medical need, and discusses the option and circumstances surrounding the compounding of a nimodipine oral solution, a U.S. Food and Drug Administration–approved indication for the treatment of subarachnoid hemorrhages.

Related Keywords: Linda F. McElhiney, PharmD, RPh, MSP, FIACP, FASHP, FACA, DPLA, nimodipine, dihydropyridine calcium channel blocker, formulations, US Food and Drug Administration, FDA, DQSA, subarachnoid hemorrhage, bleeding in brain, drug safety, dosage forms, adverse effects

Related Categories: FORMULATIONS, LEGAL, ADVERSE DRUG EVENTS, HEMOSTASIS, BLEEDING, ANTICOAGULATION, NEUROLOGY

Printer-Friendly Version

Title/Author (Click for Abstract / Details / Purchase)	Issue/Page View/Buy
Related Articles from IJPC
Nimodipine Compounded Oral Suspension: A True Documented Medical Need McElhiney Linda F	Mar/Apr 2019 Pg. 106-111
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances Miller David G	Jul/Aug 2015 Pg. 303-305
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Allen Loyd V Jr	Jul/Aug 2016 Pg. 351 View Sample
Preventing Medication Errors with Nimodipine by Compounding Proper Dosage Forms McElhiney Linda F	Sep/Oct 2013 Pg. 364-368
Nimodipine 30-mg Capsules Allen Loyd V Jr	Jan/Feb 2014 Pg. 65
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Allen Loyd V Jr	Sep/Oct 2017 Pg. 356
Pharmacies on the Frontline: Responding to the COVID-19 Pandemic McElhiney Linda F	Jul/Aug 2020 Pg. 287-295
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Allen Loyd V Jr	Nov/Dec 2015 Pg. 487-488
The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter Miller David G	May/Jun 2014 Pg. 208
U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies Yoch Doug	Mar/Apr 2017 Pg. 95-102
Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed Brunner Scott	Jul/Aug 2020 Pg. 296-297
Nimodipine 3-mg/mL Oral Solution Allen Loyd V Jr	Sep/Oct 2015 Pg. 407
Prevention Is the Best Medicine: Don J. Bottoni, RPh, FACA, FIACP Bottoni Don J	Jan/Feb 2004 Pg. 22-27
U.S. Food and Drug Administration Inspection Authority: How to Know Whether U.S. Food and Drug Administration Inspectors Are Crossing the Line Snow Stephen T, Stannard Robert W, Bellis Jennifer, Moss Carrie A	Jan/Feb 2019 Pg. 32-33
Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1 Allen Loyd V Jr	Sep/Oct 2015 Pg. 389-390
The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone Brunner Scott	Jan/Feb 2023 Pg. 22-23
Standard Operating Procedure: U.S. Food and Drug Administration Inspection--Releasing a Sample to the U.S. Food and Drug Administration Kupiec Tom, Kemp Jesse	Jul/Aug 2007 Pg. 326-327
U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List)	Nov/Dec 2016 Pg. 457-458
U.S. Food and Drug Administration Requests for Input on HR 3204 Enactment: The Drug Quality and Security Act of 2013 Miller David G	Jan/Feb 2014 Pg. 35-36
Nonsterile Basics of Compounding: Using U.S. Food and Drug Administration-approved Commercial Products as Ingredients Allen Loyd V Jr	Nov/Dec 2023 Pg. 474-481
Return to Top